Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

What Was Tested

The trial (phase 3) is built around Semaglutide.

It had three arms (groups): one (experimental), one (experimental) and one (active comparator).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 420 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Aged ≥ 18 years old (based on the date of signing the informed consent form), male or female. For subjects not diagnosed with type 2 diabetes at screening, the following criteria must be met:. Comorbidity of one or more of the following: hyperglycemia (see Appendix 1 for definition), hypertension, dyslipidemia (see Appendix 2 for definition), or fatty liver; ②Weight-bearing joint pain;. Weight-related obstructive sleep apnea syndrome. For subjects with type 2 diabetes at screening, the following criteria must be met simultaneously:.

The full record lists 8 inclusion and 18 exclusion criteria; among the exclusions: for subjects without type 2 diabetes at screening, the following situations are excluded:; diagnosis of any type of diabetes (excluding gestational diabetes) prior to screening; for subjects with type 2 diabetes at screening, the following situations are excluded:.

How the Study Was Run

Design: randomized, parallel-group and open-label.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2025-09-23 with completion listed for 2027-06-30.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Percentage change in body weight from baseline after 52 weeks (W) of treatment (time frame: From Week 0 to Week 52).

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Semaglutide in 420 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.